The HeLa cell line is useful because its cells divide indefinitely, grow quickly, tolerate routine laboratory handling, and support many kinds of experiments. It is complicated because the cells were taken from Henrietta Lacks without her knowledge, later raised genetic privacy concerns, and can contaminate other cell cultures.
To understand HeLa, you need to examine the biology and the human story together. The same traits that turned these cells into a dependable research tool also made them unusually aggressive inside laboratories. Their history can help you understand why consent, tissue use, genomic privacy, and accurate cell identification remain central concerns in medical research.
Who Was Henrietta Lacks, And How Did HeLa Begin?
Henrietta Lacks was a 31-year-old Black tobacco farmer who received treatment for an aggressive cervical adenocarcinoma at Johns Hopkins Hospital in 1951. During her treatment, tissue samples from her tumor were collected and provided to researchers without her knowledge or consent. When you see the name “HeLa,” you’re seeing the first two letters of her first and last names. Her identity, however, remained largely unknown to the public for years.
Researchers had attempted to grow human cells outside the body before, but most samples died after a limited number of divisions. Lacks’ tumor cells behaved differently: they continued dividing at a striking rate under laboratory conditions. George Gey’s laboratory recognized that the cells could become a renewable research resource and began distributing them to other scientists. That decision helped establish HeLa as one of the most widely used human-derived cell lines.
Why Are HeLa Cells Considered Immortal?
HeLa cells are called “immortal” because they can keep dividing under suitable laboratory conditions instead of reaching the usual limit on cell division. The term refers to biological immortality in cell culture, not immunity from damage or destruction. Individual HeLa cells can still die from contamination, unsuitable conditions, or experimental treatments. The cell population survives because new cells continue replacing the ones that are lost.
Normal human cells lose small sections of protective chromosome ends called telomeres whenever they divide. Once those telomeres become too short, the cells enter senescence and stop multiplying. HeLa cells have active telomerase, an enzyme that rebuilds telomeres and allows repeated division. This continuing repair process is one reason the HeLa cell line can be maintained across generations of laboratory cultures.
How Are HeLa Cells Different From Normal Human Cells?
HeLa cells came from human tissue, but they don’t represent healthy human cells. They originated in an aggressive cancer and contain extensive genetic changes that alter growth, chromosome structure, and cell-cycle control. A normal human cell usually contains 46 chromosomes. HeLa cells commonly have a hyper-triploid chromosome count of roughly 76 to 80.
Human Papillomavirus 18 (HPV-18) deoxyribonucleic acid (DNA) became integrated into the tumor-cell genome near the MYC oncogene, disrupting the systems that normally restrain cell growth. HeLa cells also show chromothripsis, a process involving chromosome shattering and extensive rearrangement. These changes help explain the cells’ aggressive behavior, yet they also limit what you can infer from them. Results produced in HeLa cells don’t automatically describe how healthy cells, other cancer cells, or an entire human body will respond.
Why Have HeLa Cells Been So Useful In Medical Research?
HeLa cells give researchers a renewable, fast-growing supply of human-derived cancer cells that can be shared across laboratories. You can expose them to viruses, medicines, radiation, genetic changes, and altered environmental conditions without repeatedly collecting new tissue from patients. Their hardiness also made them easier to ship when cell-culture methods were less advanced. Researchers could repeat experiments and compare findings using cultures descended from the same original sample.
Jonas Salk used HeLa cells during testing of the first polio vaccine, connecting the cell line to one of its best-known medical contributions. Research involving HeLa also supported the study of HPV’s role in cervical cancer and work that led to HPV vaccines. Scientists have used the cells to examine how Human Immunodeficiency Virus (HIV) infects cells, assess cancer treatments, map genes, study in vitro fertilization (IVF), and measure cellular responses to zero gravity. These contributions don’t mean that HeLa alone produced every discovery, but the cells supplied a practical testing system for many research programs.
Why Are HeLa Cells A Contamination Problem?
The same survival traits that make HeLa useful also allow the cells to overtake other laboratory cultures. A tiny transfer from a tool, lab coat, airborne particle, or contaminated work surface can introduce HeLa into another dish. Since the cells grow quickly, they can outcompete the original cell population before researchers notice the change. An experiment labeled as one tissue type may then be measuring HeLa cells instead.
Estimates suggest that 10% to 20% of research cell lines may be contaminated with HeLa or may have been misidentified as another line. Contamination has wasted research funds, undermined experimental findings, and contributed to paper retractions. Researcher Walter Nelson-Rees drew attention to the problem during the 1970s, pressing laboratories to verify cell identity rather than trust a label. Today, careful laboratories authenticate cell lines, separate cultures, clean equipment, document handling, and review unusual growth patterns.
Did Henrietta Lacks Consent, And Did Her Family Receive Compensation?
Henrietta Lacks did not give informed consent for her tumor cells to be collected and used in research. At the time, no legal or regulatory requirement compelled doctors to obtain consent before using discarded tissue in this manner. That historical fact explains how the collection occurred, but it doesn’t remove the harm experienced by her family. Her cells became a commercial research resource long before her relatives understood what had happened.
The Lacks family later challenged companies that profited from products connected to HeLa. Thermo Fisher Scientific reached a confidential settlement with the family after a lawsuit argued that the company benefited from cells taken without permission. Since the terms remain private, you cannot read the settlement as a public ruling that created a broad ownership right over human tissue. It still marked a major change in how the family’s claims were recognized.
Johns Hopkins has stated that it did not sell or profit from the HeLa cell line, and it has acknowledged that the cells were collected without Henrietta Lacks’ consent. The World Health Organization (WHO) later presented a posthumous Director-General’s Award recognizing her contribution to global health. Recognition cannot undo the original lack of choice or the years during which her family lacked information. It can, however, keep her identity from being reduced to a laboratory label.
Why Did The HeLa Genome Create A Privacy Dispute?
The HeLa genome raised privacy concerns because genetic data from one person can reveal information connected to biological relatives. Researchers published a full HeLa genome sequence without first securing the Lacks family’s agreement. The publication renewed questions about whether removing names from a tissue sample provides enough protection. With detailed genomic data, privacy extends beyond the person whose cells were collected.
The National Institutes of Health (NIH) negotiated an agreement with the Lacks family covering access to full HeLa genomic sequence data in a controlled database. Family representatives gained a voice in reviewing requests from researchers who want access. The agreement did not erase the earlier publication, but it established a more respectful process for managing sensitive data. It also showed you why genomic privacy cannot be treated as a simple matter of removing a patient’s name.
What Is The Legal And Ethical Status Of HeLa Cells Today?
Researchers can continue using HeLa cells, but their use now carries responsibilities tied to scientific accuracy, privacy, attribution, and respect for the Lacks family. The cells remain part of laboratory collections around the world, and access to certain genomic data is controlled through the NIH agreement. The confidential commercial settlement did not publicly define a universal legal rule for every human tissue sample. Questions about tissue control still depend on applicable laws, consent documents, research procedures, and the type of data involved.
For you, the central lesson is that a scientifically useful sample isn’t separated from the person who supplied it. Good research practice requires accurate cell authentication, transparent tissue policies, secure genomic data, and understandable consent procedures when consent applies. Researchers also need to distinguish findings from HeLa cells from findings that apply to normal human biology. Scientific value and human dignity can be protected through deliberate laboratory and data-management decisions.
Why Are HeLa Cells So Useful In Scientific Research?
- They divide indefinitely under suitable conditions.
- They grow quickly and tolerate routine lab handling.
- They can be infected or genetically altered for experiments.
- They provide a repeatable supply of human-derived cancer cells.
What You Should Remember About The HeLa Legacy
The HeLa cell line remains useful because it supplies fast-growing, durable cells for repeatable laboratory experiments. Its unusual biology comes from active telomerase, HPV-18 integration, abnormal chromosome numbers, and extensive genetic rearrangement. Those same traits demand caution because HeLa can contaminate other cultures and doesn’t represent normal human tissue. Its origin also shows what can happen when researchers separate biological material from consent, privacy, and personal identity. Understanding HeLa means recognizing Henrietta Lacks as a person whose cells changed medical research, not merely as the source of an immortal cell line.
References
- Johns Hopkins Medicine: Henrietta Lacks, Her Cells, Her Legacy
- National Human Genome Research Institute: HeLa Cell Line
- World Health Organization: Posthumous Award to Henrietta Lacks
- Nature: HeLa Genome Data Access Agreement
- STAT: Lacks Family and Thermo Fisher Scientific Settlement
- The Henrietta Lacks Foundation.
Nirdosh Jagota is Managing Partner at GRQ Biotech Advisors with 30+ years in the biotech industry. A former executive at Amgen, Genentech/Roche, Merck, and Pfizer, he has led >25 NDAs/BLAs/MAAs and hundreds of INDs across global regulatory, quality, and compliance.

